借助药物再利用和递送系统增强抗癌免疫反应。
Enhancing the anticancer immune response with the assistance of drug repurposing and delivery systems.
机构信息
Department of Liver Surgery and Transplantation, and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
The Center for Microbes, Development and Health, Key Laboratory of Molecular Virology and Immunology, Chinese Academy of Sciences, Shanghai, China.
出版信息
Clin Transl Med. 2023 Jul;13(7):e1320. doi: 10.1002/ctm2.1320.
BACKGROUND
The immune system plays a pivotal role in the initiation, evolution, invasion and metastasis of cancer. Therapeutics aiming at modulating or boosting anticancer immune responses have experienced immense advances during the past decades, for example, anti-PD-1/PD-L1 monoclonal antibodies.
MAIN BODY
Concomitant with advancements in the understanding of novel mechanisms of action, conventional or emerging drugs bearing the potential to be repurposed for enhancing anticancer immunity have been identified. Meanwhile, ongoing advances in drug delivery systems enable us to utilise novel therapeutic strategies and impart drugs with fresh modes of action in tumour immunology.
CONCLUSION
Herein, we systemically review these kinds of drugs and delivery systems that can unleash the anticancer response through various aspects, including immune recognition, activation, infiltration and tumour killing. We also discuss the current caveats and future directions of these emerging strategies.
背景
免疫系统在癌症的发生、发展、侵袭和转移中起着关键作用。在过去几十年中，旨在调节或增强抗癌免疫反应的疗法取得了巨大进展，例如抗 PD-1/PD-L1 单克隆抗体。
主要内容
随着对新型作用机制的理解的进步，已经确定了具有重新用于增强抗癌免疫潜力的传统或新兴药物。同时，药物输送系统的不断进步使我们能够利用新的治疗策略，并为肿瘤免疫学中的药物赋予新的作用模式。
结论
本文系统地综述了这些能够通过免疫识别、激活、浸润和肿瘤杀伤等多种途径释放抗癌反应的药物和输送系统。我们还讨论了这些新兴策略的当前局限性和未来方向。
Zotero 插件